Physician profile
Robert Koser
NPI 1861409377
$722.99
in general payments reported to CMS, 2019-2025
14 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $91.56 · 2021: $20.82 · 2022: $16.50 · 2023: $23.21 · 2024: $57.62 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.21 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $121.02 | 2025 | |
| Pfizer INC. | $89.22 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.91 | 2024-2025 | Xifaxan |
| United Therapeutics Corporation | $60.80 | 2019 | |
| Lilly USA, LLC | $27.64 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $23.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.82 | 2021 | |
| Mirum Pharmaceuticals, INC. | $20.45 | 2025 | Cholbam |
| Allergan, INC. | $17.66 | 2019 | |
| Biogen, INC. | $17.61 | 2020 | |
| Acadia Pharmaceuticals INC | $17.52 | 2025 | Daybue |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.50 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Koser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.